Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma
| Autor: | W. J. Xiao, Dingwei Ye, Y. P. Hong, Xu-dong Yao, Hailiang Zhang, Zuopeng Wang, Shi-lin Zhang, Yun-Song Zhu, Bo Dai, G. H. Shi |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Adult Male Vascular Endothelial Growth Factor A Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Kaplan-Meier Estimate urologic and male genital diseases Targeted therapy chemistry.chemical_compound Young Adult Conditional survival Renal cell carcinoma Internal medicine Outcome Assessment Health Care medicine Humans In patient Carcinoma Renal Cell Protein Kinase Inhibitors Survival analysis Aged Proportional Hazards Models Aged 80 and over Hematology business.industry General Medicine Middle Aged medicine.disease Prognosis Kidney Neoplasms Vascular endothelial growth factor Survival Rate chemistry Female business |
| Zdroj: | Journal of cancer research and clinical oncology. 138(11) |
| ISSN: | 1432-1335 |
| Popis: | Conditional survival (CS) offers more relevant prognostic information for patients once they have survived for some time. The objective of this study was to determine the CS for advanced renal cell carcinoma (RCC) patients treated with vascular endothelial growth factor-targeted therapy.A total of 345 patients treated between 2006 and 2011 fulfilled the inclusion criteria and were reviewed for analyses. The 1-year conditional and actual survival rates were calculated for survivors from treatment to month 24. Subgroup-specific CS rates were generated after adjustment of the covariate influence. The Cox proportional hazard models were used to assess the prognostic factors at baseline and 1-year landmark.The probabilities of surviving an additional year given survival to 6, 12, 18, and 24 months were 72.2, 76.3, 78.2, and 78.6 %, respectively. Remarkable increase in CS was observed in patients initially classified as intermediate or poor risk according to Heng risk groups. For patients survived 24 months after treatment, the adjusted CS for the following year was over 80 % regardless of initial risk attribution. Compared to baseline analysis, Heng risk groups were less predictive of survivorship after surviving 1 year. The addition of disease control status to multifactorial model significantly improved survival estimation for 1-year survivors (p0.01).CS provides useful information regarding life expectancy for survivors of advanced RCC treated with targeted therapy. Furthermore, disease control status within a specific period of time is critical to the prediction of subsequent survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink